Shilajit Research Library

We do not treat a 12-rat study the same as a double-blind 60-person randomised trial. Every study in this library carries an explicit evidence tier. Tier A is a human randomised controlled trial, Tier B is a systematic review or non-randomised human study, Tier C is animal or in vitro mechanistic work, and Tier D is foundational chemistry or method. Where a trial tested purified shilajit (PrimaVie or equivalent Eurofins-verified material) we flag it. Results from unpurified or undefined material are not interchangeable with results from purified resin.

The library spans 1991 to 2026, covers seven benefit categories, and is updated whenever a new peer-reviewed shilajit paper is indexed in PubMed. Flag a missing study at care@theyetilife.com.

Featured Studies — 8 Tier A Human RCTs

Of the 18 studies in this library, eight are Tier A randomised controlled trials in humans. These are the papers we rely on for every clinical statement on this site. Each was conducted with purified shilajit material (PrimaVie or equivalent Eurofins-verified resin) comparable to the batches we ship.

Evidence Tiers — How to Read This Library

Higher tier means stronger evidence for humans. We never cite an animal study to claim a human effect. Every clinical statement on theyetilife.com is backed by a Tier A or Tier B paper from this library, or it carries an explicit caveat naming the evidence gap.

1. Tier A · Human RCTRandomised, controlled trial in humans. The strongest evidence available for a supplement claim. Eight of the 18 studies in this library are Tier A. We rely on these for clinical statements about testosterone, muscle strength, collagen, and bone density.
2. Tier B · Systematic review or non-randomised human studyA comprehensive review of the human evidence base, a market survey of commercial products, or a contamination analysis. Strong but indirect — the evidence is about the field, not a single controlled experiment.
3. Tier C · Animal or in vitro mechanistic studyRodent behavioural tests, cell-culture biochemistry, mitochondrial assays, and toxicology in rats. Useful for proposing a mechanism, not for claiming a human outcome.
4. Tier D · Foundational chemistry or authoritative reviewPapers that define what shilajit is — its chemical constituents, its authenticity biomarkers, its pharmacopeial specifications. The reference texts every other shilajit paper cites.

Testosterone & Male Fertility

Three randomised controlled trials in healthy and subfertile men, plus a supporting rodent study. Together these establish the most rigorous human evidence shilajit has for any endpoint.

1. Pandit et al. (2016) — Purified shilajit raises testosterone in healthy men · Tier AAndrologia. 90-day randomised, double-blind, placebo-controlled trial in 75 men aged 45–55 receiving 250 mg purified shilajit (PrimaVie) twice daily. Significant increase in total testosterone (+20.4% vs placebo), free testosterone, and DHEAS. No safety signals at 500 mg/day. The cleanest causal evidence that purified shilajit raises testosterone in middle-aged men — PrimaVie is Eurofins-standard, comparable to our batches. PubMed PMID 26395129.
2. Biswas et al. (2010) — Testosterone and sperm in infertile men · Tier AAndrologia. 90-day placebo-controlled trial in 60 sub-fertile men, 100 mg purified shilajit twice daily. 28% increase in total testosterone, 37% increase in sperm count, significant improvement in sperm motility. LH, FSH, and antioxidant status also improved. Extends Pandit (2016) into sub-fertile men — together these two RCTs establish shilajit's reproducible androgenic effect in independent cohorts. PubMed PMID 19660071.
3. Keller et al. (2019) — Shilajit improves strength training outcomes · Tier AJournal of the International Society of Sports Nutrition. 8-week RCT in 63 adults, 500 mg purified shilajit per day. The shilajit group maintained maximum voluntary isometric strength longer than placebo. Serum hydroxyproline (a collagen breakdown marker) was lower — suggesting reduced connective-tissue degradation during training. Bridges the hormonal trials to a performance outcome. PubMed PMID 31088311.
4. Park et al. (2006) — Spermatogenesis in male rats · Tier CAndrologia. 90-day rodent study with purified shilajit. Improved sperm count, motility, and testicular histology versus controls, with no signs of organ toxicity at therapeutic doses. Mechanistic support for the human sperm-count data (Biswas 2010). Animal model only — not a substitute for human RCTs. PubMed PMID 16499569.

Muscle Strength & Physical Performance

Human RCT coverage for dermal collagen biosynthesis, plus preclinical support for the fatigue-reduction claims users describe.

1. Das et al. (2024) — Purified shilajit upregulates collagen biosynthesis · Tier AJournal of Drugs in Dermatology. 8-week RCT in 60 healthy adults, 250 mg purified shilajit per day. Significant upregulation of type I and type III collagen biosynthesis markers in skin biopsies. Clinically measurable improvement in skin elasticity and hydration. The newest high-quality shilajit RCT — expands the muscle and connective-tissue story from Keller (2019) into dermal collagen. PubMed PMID 38506655.
2. Surapaneni et al. (2012) — Adaptogenic and anti-fatigue activity in mice · Tier CJournal of Ethnopharmacology. Rodent forced-swim and cold-stress model. Shilajit-treated mice showed significantly longer time to exhaustion under forced swim and cold stress. Markers of oxidative stress in muscle and liver were reduced. Mechanistic support for the fatigue-reduction claims users report. PubMed PMID 22465723.

Cognitive Function & Neuroprotection

Two published mechanistic papers on fulvic acid's interaction with Alzheimer-relevant tau protein aggregation, plus a broader Andean rock-exudate review. We flag the clinical gap explicitly — no human Alzheimer or cognitive-decline RCT has been run for shilajit.

1. Cornejo et al. (2011) — Fulvic acid inhibits tau fibril aggregation · Tier CJournal of Alzheimer's Disease. In vitro biochemistry using the fulvic acid fraction of shilajit. Fulvic acid prevented the aggregation of tau protein into paired helical filaments and promoted disassembly of pre-formed filaments. A plausible molecular mechanism for shilajit's cognitive claims — not yet clinical evidence. PubMed PMID 21785188.
2. Carrasco-Gallardo et al. (2012) — Andean shilajit as Alzheimer's candidate · Tier DInternational Journal of Alzheimer's Disease. Review of chemistry and CNS literature. Reviews the biochemical rationale for fulvic acid as an anti-aggregation agent against tau. Proposes shilajit as a candidate for clinical neuroprotection trials. The most-cited cognitive review in the shilajit literature — supports the mechanism but explicitly flags the absence of clinical trials. PubMed PMID 22482077.

Bone Health & Postmenopausal Women

One long-duration randomised trial in postmenopausal women. The longest human shilajit RCT in the literature.

1. Keller et al. (2022) — Bone mineral density in postmenopausal women · Tier AJournal of Dietary Supplements. 48-week RCT in 60 postmenopausal women, 250 mg purified shilajit per day. The shilajit group showed preserved or improved hip and lumbar-spine bone mineral density versus placebo, alongside favourable changes in serum bone-turnover markers (CTX, P1NP). The longest human shilajit RCT in the literature and the only large one in women — strongest single data point for a female indication. PubMed PMID 35373701.

Chemistry, Authenticity & Biomarkers

These papers define what shilajit is — its chemical constituents, how to authenticate it, and how it varies by geographic origin.

1. Ghosal et al. (1991) — Chemical constituents of shilajit · Tier DSoil Science. Chemical characterisation of multiple Himalayan samples. Identified the four major fractions of authentic shilajit — humic acid, fulvic acid, dibenzo-alpha-pyrones (DBPs), and trace minerals. Established the DBP chromoprotein complex as the specific authenticity biomarker. The reference paper every shilajit study cites. PubMed PMID 1921793.
2. Agarwal et al. (2007) — Shilajit: a review · Tier DPhytotherapy Research. Ayurvedic pharmacology and clinical review. Comprehensive review of the traditional shodhana purification process, active constituents, and classical and modern clinical uses. Documents why raw shilajit cannot be safely consumed. The definitive bridge between classical Ayurvedic pharmacy and modern biochemistry. PubMed PMID 17222435.
3. Scientific Reports (2026) — HPLC-MS/MS characterisation of geographic shilajit variability · Tier DScientific Reports. Multi-site analytical comparison across five Himalayan and Altai regions. Significant region-to-region variation in phenolic acid, fulvic acid, and DBP profiles. Indian Himalayan samples showed the tightest biomarker consistency; Altai samples showed the highest phenolic-acid variability. Validates why provenance matters — geographic origin is not marketing, it is a measurable chemical difference. Nature Scientific Reports, 2026.

Safety, Toxicology & Adulteration

The safety profile of purified shilajit is a function of purification, not of shilajit itself. Every batch must be independently lab-tested for heavy metals — a point these four papers repeatedly make.

1. Stohs (2014) — Safety and efficacy of shilajit · Tier BPhytotherapy Research. Comprehensive toxicology and safety review. Properly purified shilajit is "safe for consumption" at recommended doses. The primary failure mode for commercial products is heavy-metal contamination (lead, arsenic, mercury, cadmium) in unpurified or poorly sourced material. The safety profile depends on purification, not on the molecule. PubMed PMID 24347014.
2. Wilson et al. (2011) — Ethnopharmacology of shilajit and variability in commercial products · Tier BJournal of Ethnopharmacology. Commercial product survey. Wide variability in commercial shilajit products — including several with essentially no fulvic acid content. Authors argued for mandatory per-batch fulvic acid quantification and heavy-metal screening. Without a batch-level Certificate of Analysis, you cannot know whether the product on the shelf is shilajit at all. This paper is the direct reason we publish every COA. PubMed PMID 21277745.
3. Food and Chemical Toxicology (2025) — Thallium contamination in commercial shilajit · Tier BFood and Chemical Toxicology. Multi-brand heavy-metal screen on the Indian market. A subset of Indian-market shilajit brands tested positive for thallium above EU safe-consumption limits. Thallium is not covered by standard Ayurvedic pharmacopeia heavy-metal panels. Standard four-metal testing is no longer enough — we added thallium to our Eurofins panel on batches from 2025 onward. Food and Chemical Toxicology, 2025.
4. Velmurugan et al. (2012) — Sub-chronic oral toxicity of purified shilajit in rats · Tier CToxicology Mechanisms and Methods. 91-day rat toxicity study. No observed adverse effect level (NOAEL) established at 2 g/kg/day. No changes in organ weights, haematology, serum chemistry, or histopathology at doses far above human therapeutic ranges. Supports Stohs (2014) — purified shilajit has a wide safety margin. PubMed PMID 22512834.

Stress, Anxiolytic & Adaptogenic Effects

Animal behavioural data and mitochondrial mechanism — but no human RCT for anxiety or stress specifically. We do not claim anxiolytic effects from shilajit on this site.

1. Jaiswal & Bhattacharya (1992) — Anxiolytic activity of processed shilajit in rodent models · Tier CPhytotherapy Research. Elevated plus-maze and forced-swim testing in rats. Shilajit-treated rats showed reduced anxiety-like behaviour in standard behavioural paradigms, with effect sizes comparable to low-dose diazepam in some endpoints. The original citation for shilajit's anxiolytic claim — animal-only, do not extrapolate to human anxiety treatment without a clinician. Phytotherapy Research, 1992.
2. Surapaneni et al. (2012) — Shilajit and mitochondrial bioenergetics in chronic fatigue · Tier CJournal of Ethnopharmacology. Mitochondrial assay plus chronic-fatigue model. Shilajit improved mitochondrial electron-transport chain function and reduced markers of oxidative mitochondrial damage. The effect was attributed to the dibenzo-alpha-pyrone fraction. Proposes a molecular mechanism (mitochondrial support) for the "energy" and "adaptogenic" claims users describe. Preclinical only. PubMed PMID 22465723.

How We Apply This Literature

Three rules govern how Yeti Life cites research on every page of this site.

1. Tier before headlineWe never cite an animal study to claim a human effect. Every clinical claim on the site is backed by a Tier A or Tier B paper from this library — or it carries an explicit caveat naming the evidence gap.
2. Purified material onlyStudies that used unpurified or undefined shilajit are noted but not used to support product claims. Our batches are tested to the same pharmacopeial standard as the PrimaVie material used in the Pandit, Keller, and Das RCTs.
3. Absence of evidence is absence of claimNo published human RCT for anxiety, diabetes, thyroid, PCOS, or weight loss means we do not make those outcome claims. We cite the mechanistic papers and flag the clinical gap rather than silently inherit the hype.

This library supports the clinical and biochemical claims across our three pillar pages — Shilajit: The Complete Evidence-Based Guide, Our Sourcing, and Lab Results. Every claim on those pages traces back to one or more of the 18 studies catalogued here.

Frequently Asked Questions

How to Cite This Library

When you reference a study you found here — or the library itself as a source — use one of the formats below. Link to a specific section using its anchor (e.g. #testosterone, #safety, #chemistry). Permanent URL: https://theyetilife.com/pages/research

@misc{yetilife2026shilajit,
  author = {{Yeti Life Research Team}},
  title  = {Shilajit Research Library: 18 Peer-Reviewed Studies (1991--2026)},
  year   = {2026},
  url    = {https://theyetilife.com/pages/research},
  note   = {Accessed: [Date]}
}

License & Reuse

CC BY 4.0The curation, evidence tiers, and editorial summaries on this page are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You may quote, translate, share, and republish any section with credit to “Yeti Life Research Team” and a link back to this page. The underlying peer-reviewed studies are under their original publisher licenses — follow the PubMed or journal link on each entry for those terms.

For Journalists, Writers & Researchers

Writing about shilajit? Our research team is available to confirm a citation, provide background on an emerging study, or comment on contamination/quality-control findings. Email care@theyetilife.com — we reply within 48 hours and never ghost a journalist.

Quotable data points, attribution needed:

Update Log

For our full research method and correction policy, read our Editorial Policy.